Brief: Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker And Preclinical Data Supporting A Phase 2 Clinical Trial With Ct1812 In Geographic Atrophy Secondary To Dry AMD
01/12/2022 12:34
Dec 1 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS PRESENTS SCIENTIFIC RATIONALE,
CLINICAL
BIOMARKER AND PRECLINICAL DATA SUPPORTING A PHASE 2 CLINICAL
TRIAL WITH CT1812 IN GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD
Source text for Eikon: ID:nGNX1pDmck
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB